FDA panel considers automated breast ultrasound
U-Systems’ somo•v automated breast ultrasound system has been scheduled for review by the Radiological Devices Panel of the FDA on April 11.
U-Systems is seeking a breast cancer screening indication for the somo•v system. Currently, somo•v is FDA-cleared for diagnostic use as an adjunct to mammography, according to the Sunnyvale, Calif.-based ultrasound developer.
The somo•v system automates the breast ultrasound imaging process for the high-volume screening environment. Exams can be reviewed on the somo•Viewer 3D workstation.
U-Systems is seeking a breast cancer screening indication for the somo•v system. Currently, somo•v is FDA-cleared for diagnostic use as an adjunct to mammography, according to the Sunnyvale, Calif.-based ultrasound developer.
The somo•v system automates the breast ultrasound imaging process for the high-volume screening environment. Exams can be reviewed on the somo•Viewer 3D workstation.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.